Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight

NCT07104383 is registered in ClinicalTrials.gov with Viking Therapeutics, Inc. as lead sponsor.

NCT NCT07104383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight
Lead sponsor
Viking Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 23, 2025
Completion date
August 1, 2027
Enrollment
1,100 (estimated)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

weight loss